Patents Assigned to Pharmascience
-
Patent number: 11773132Abstract: The present disclosure relates to a compound of formulae (I) or (II), or a pharmaceutically acceptable salt, a solvate, a hydrate thereof, a pharmaceutical composition comprising a compound of formulae (I) or (II), and use thereof, wherein various Markush groups are as described herein.Type: GrantFiled: August 30, 2018Date of Patent: October 3, 2023Assignee: Beijing Xuanyi PharmaSciences Co., Ltd.Inventors: Yuntao Song, Anrong Li, Xiaoqi Chen
-
Patent number: 11744813Abstract: The invention relates to a composition comprising: i) one or more LDH-active anion materials comprising an LDH matrix intercalated with one or more active anions, and ii) a modifier system comprising a) one or more surfactants, in combination with b) one or more compounds having the generic formula MA, where M comprises one or more positively charged ions and A comprises one or more negatively charged counter ions.Type: GrantFiled: November 4, 2021Date of Patent: September 5, 2023Assignee: Oxford Pharmascience LimitedInventors: Elizabeth King, Marcelo Leonardo Bravo Cordero, Ann Taylor-Hutchinson
-
Patent number: 11485782Abstract: Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.Type: GrantFiled: March 14, 2019Date of Patent: November 1, 2022Assignee: Beijing Xuanyi Pharmasciences Co., Ltd.Inventors: Yuntao Song, Yi Ding, Chen Dong, Zhiwei Li, John Lippincott, Ping Hui Szu
-
Patent number: 11351170Abstract: The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R1, R2, R3a, R3b, R5, R6, X1, X2, Y and n are described herein.Type: GrantFiled: August 15, 2018Date of Patent: June 7, 2022Assignee: Beijing Xuanyi PharmaSciences Co., Ltd.Inventors: Yuntao Song, Xiaoqi Chen
-
Patent number: 10272057Abstract: The invention relates to layered double hydroxide (LDH) materials and in particular to new methods of preparing improved LDH materials which have intercalated active anionic compounds (improved LDH-active anion materials). The improved LDH-active anion materials are characterized by their high degree of robustness, demonstrated by their high Particle Robustness Factor values, and by their ability to retain substantially all of the intercalated active anionic compound, in the absence of ion exchange conditions and/or at pH>4.Type: GrantFiled: April 3, 2017Date of Patent: April 30, 2019Assignee: OXFORD PHARMASCIENCE LIMITEDInventors: Claire Thompson, Marcelo Leonardo Bravo Cordero, Dermot Michael O'Hare
-
Publication number: 20190076366Abstract: The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.Type: ApplicationFiled: April 3, 2018Publication date: March 14, 2019Applicant: Pharmascience, Inc.Inventors: Mathew Philip, Naresh Talwar
-
Publication number: 20180179210Abstract: The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.Type: ApplicationFiled: May 27, 2016Publication date: June 28, 2018Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
-
Publication number: 20180117158Abstract: A modified release orally administrable abuse-deterrent pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient and konjac glucomannan. The active pharmaceutical ingredient can be selected from a number of compounds but is generally aimed to be a compound which is subject to widespread abuse such as opioids.Type: ApplicationFiled: December 27, 2017Publication date: May 3, 2018Applicant: Pharmascience Inc.Inventors: Krishna Hari Bhandari, Naresh Talwar
-
Patent number: 9822120Abstract: The present invention relates to a novel family of protein kinase inhibitors of Formula I: as well as to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.Type: GrantFiled: November 20, 2014Date of Patent: November 21, 2017Assignee: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Patent number: 9796716Abstract: The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.Type: GrantFiled: May 28, 2013Date of Patent: October 24, 2017Assignee: PHARMASCIENCE, INC.Inventors: Alain Laurent, Yannick Rose, James B. Jaquith
-
Patent number: 9795608Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.Type: GrantFiled: September 12, 2016Date of Patent: October 24, 2017Assignee: PHARMASCIENCE, INC.Inventors: Alain Laurent, Yannick Rose
-
Publication number: 20170158697Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated.Type: ApplicationFiled: November 26, 2014Publication date: June 8, 2017Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Patent number: 9642919Abstract: The invention relates to layered double hydroxide (LDH) materials and in particular to new methods of preparing improved LDH materials which have intercalated active anionic compounds (improved LDH-active anion materials). The improved LDH-active anion materials are characterized by their high degree of robustness, demonstrated by their high Particle Robustness Factor values, and by their ability to retain substantially all of the intercalated active anionic compound, in the absence of ion exchange conditions and/or at pH>4.Type: GrantFiled: October 1, 2013Date of Patent: May 9, 2017Assignee: OXFORD PHARMASCIENCE LIMITEDInventors: Claire Thompson, Marcelo Leonardo Bravo Cordero, Dermot Michael O'Hare
-
Patent number: 9624239Abstract: The present invention relates to a novel family of inhibitors of protein kinases of Formula (1) wherein X is selected from CH2, O, S(0)n, or NR6; and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src, Btk and Lck protein kinase families.Type: GrantFiled: April 3, 2012Date of Patent: April 18, 2017Assignee: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
-
Patent number: 9562025Abstract: The present invention relates to compounds having at least one (substituted phenyl)-propenal moiety. The compounds are useful in treating a subject suffering from an androgen receptor-associated medical condition, e.g., inflammation, acne, alopecia, hirsutism, wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease), unwanted immune response, immune disorder, or cancer.Type: GrantFiled: February 16, 2016Date of Patent: February 7, 2017Assignee: Allianz Pharmascience Ltd.Inventors: Charles Shih, Qian Shi, Hui-Kang Wang
-
Publication number: 20170014340Abstract: Orally disintegrating medicaments comprising Nabilone allow for improved treatment of nausea arising from chemo therapy for cancer. The medicaments comprise appropriate excipients such that the medicament disintegrates in the mouth in 30 seconds or less, while exhibiting sufficient stability for storage. In a preferred embodiment, the medicament is in the form of a tablet formed from granules. The granules consist of an intra-granular fraction comprising nabilone, mannitol, and polyvinyl pyrrolidone and an extra-granular fraction comprising mannitol, calcium silicate, crospovidone, and magnesium stearate. Processes for manufacturfing such medicaments are also disclosed.Type: ApplicationFiled: March 4, 2015Publication date: January 19, 2017Applicant: Pharmascience Inc.Inventors: Ousmane Diallo, Mathew Philip, Naresh Talwar
-
Publication number: 20160375027Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Applicant: PHARMASCIENCE, INC.Inventors: Alain LAURENT, Yannick ROSE
-
Publication number: 20160289236Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.Type: ApplicationFiled: November 19, 2014Publication date: October 6, 2016Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Publication number: 20160280711Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.Type: ApplicationFiled: November 20, 2014Publication date: September 29, 2016Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Patent number: 9447102Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.Type: GrantFiled: July 3, 2013Date of Patent: September 20, 2016Assignee: PHARMASCIENCE, INC.Inventors: Alain Laurent, Yannick Rose